Chronic Traumatic Encephalopathy

Chronic traumatic encephalopathy (CTE) is a tauopathy associated with repetitive head impacts. Once recognized only in boxers (“dementia pugilistica”), CTE has been increasingly identified in football players, hockey players, military veterans, and others exposed to repetitive head trauma. The pathology is distinctive — perivascular tau pathology in the depths of cortical sulci, particularly the frontal cortex — and the clinical syndrome includes behavioral, cognitive, and mood disturbances. The 2021 second NINDS/NIBIB consensus refinement established the current pathologic definition of CTE — specifically requiring neuronal p-tau in the perivascular sulcal-depth lesion, and research continues to refine clinical diagnosis and risk factors. This page covers CTE pathology and the spectrum of trauma-related neurodegenerative disease.

Pathology of CTE

Pathologic Hallmark

The 2021 NINDS/NIBIB consensus criteria define CTE pathologically by:

  • Pathognomonic lesion: perivascular p-tau at the depths of cortical sulci that includes neuronal p-tau, with or without associated astrocytic p-tau (thorn-shaped astrocytes). The lesion concentrates around small vessels in superficial cortical layers (II–III), where biomechanical stress is maximal during head impact. The neuronal p-tau requirement is what distinguishes the pathognomonic CTE lesion from ARTAG (aging-related tau astrogliopathy), which is astrocytic-only and is common in older brains without CTE risk.
  • Phospho-tau (AT8) IHC reveals the tau.
  • Both 3R and 4R tau isoforms (mixed tauopathy).

Distribution

  • Frontal cortex (especially superior/middle frontal).
  • Temporal cortex.
  • Insular cortex.
  • Inferior parietal cortex.
  • Hippocampus (in advanced disease).
  • Subcortical: medial thalamus, hypothalamus, substantia nigra, locus coeruleus.
  • Distribution follows neuropathologic staging (McKee stages I-IV).

McKee Stages

  • Stage I: focal perivascular foci of tau in frontal cortex.
  • Stage II: multiple foci of tau in frontal, temporal, septum pellucidum often abnormal.
  • Stage III: widespread cortical tau + medial temporal involvement.
  • Stage IV: severe tau pathology widespread + neurodegeneration with atrophy.

Other Findings

  • Cavum septum pellucidum (often).
  • Hippocampal sclerosis (advanced disease).
  • Coexisting TDP-43 inclusions (some patients).
  • Coexisting AD pathology (in older patients).
  • Cortical atrophy in advanced disease.

Clinical Syndrome (Traumatic Encephalopathy Syndrome — TES)

2021 NINDS-defined research criteria for clinical CTE/TES:

  • Substantial exposure to repetitive head impacts.
  • Core clinical features: cognitive impairment OR neurobehavioral dysregulation (impulsivity, aggression, mood lability, rage).
  • Supportive: episodic memory impairment, executive dysfunction, motor signs (parkinsonism, gait), psychiatric symptoms (depression, suicidality), substance abuse.
  • Progressive course.
  • Not better explained by other condition.

Differential Diagnosis

  • Frontotemporal dementia (especially bvFTD).
  • Alzheimer disease.
  • Mood / psychiatric disorders.
  • Substance use disorders.
  • Effects of acute concussion or TBI.

Often distinguishing requires neuropathologic examination at autopsy.

Mechanism Hypothesis

Repetitive concussive and subconcussive impacts induce axonal injury at sulcal depths where biomechanical stress concentrates. This triggers tau hyperphosphorylation, eventual aggregation, and spread through the cortex. The perivascular pattern reflects vascular damage and BBB disruption at impact sites. Tau pathology spreads in a prion-like fashion over years.

Risk Factors

  • Cumulative number and intensity of head impacts.
  • Earlier age of exposure.
  • Duration of exposure.
  • Genetic susceptibility (APOE4 may modify risk; debated).
  • Subconcussive (not just concussive) impacts contribute.

Sports and Other Exposures

  • American football: high prevalence in former professional players studied at autopsy.
  • Boxing: classical association (“dementia pugilistica”).
  • Soccer: heading-related risk.
  • Hockey: especially fighting and body checking.
  • Rugby.
  • Military: blast injuries.
  • Domestic violence: emerging concern.

Diagnosis

Definite CTE requires neuropathologic examination at autopsy. Antemortem diagnosis remains presumptive based on:

  • Clinical history of repetitive head impacts.
  • Compatible clinical syndrome (TES).
  • Exclusion of mimics.
  • Imaging may show atrophy patterns.
  • Tau PET imaging: showing characteristic distribution may be supportive (research stage).
  • CSF and blood biomarkers (tau, neurofilament light) under investigation.

Treatment

  • No disease-modifying therapy.
  • Symptomatic management of cognitive, mood, behavioral symptoms.
  • SSRIs, mood stabilizers, sometimes anti-psychotics.
  • Cognitive rehabilitation.
  • Family and caregiver support.
  • Anti-tau immunotherapies in trials but not specifically for CTE.

Prevention

  • Reducing exposure to head impacts at all ages.
  • Rule changes in contact sports.
  • Better helmets and equipment.
  • Recognition and management of acute concussions.
  • Education about long-term risks.

Related Trauma-Related Neurodegenerative Disorders

  • Dementia pugilistica: classical CTE in boxers.
  • Post-traumatic stress disorder (PTSD): distinct but may coexist.
  • Post-concussion syndrome: subacute post-concussive symptoms; usually resolves over weeks-months.
  • Second impact syndrome: rare, devastating cerebral edema following second concussion before recovery from first.

🔍 Did You Know?

The recognition that chronic traumatic encephalopathy occurs not just in boxers but in football players, hockey players, soccer players, and military veterans has had profound implications for public health and sports policy. The seminal autopsy studies by Bennet Omalu (2005), Ann McKee (ongoing), and others demonstrated CTE in former NFL players, including some who died by suicide or under tragic circumstances. The cumulative impact of years of subconcussive contact, even without diagnosed concussions, appears sufficient to trigger the tau pathology. This realization has driven rule changes in youth and professional football, reduced practice contact, expanded concussion protocols, age limits for heading in soccer in some countries, and ongoing controversy about youth participation in contact sports. The clinical syndrome — initially mood/behavior changes, progressing to cognitive decline — typically appears years to decades after the exposure ends. The pathology can be definitively identified only at autopsy, and ongoing efforts to develop antemortem biomarkers (tau PET, plasma biomarkers) are critical. The 2021 NINDS consensus criteria standardized the neuropathologic diagnosis, allowing more rigorous research. The lesson generalizes beyond sports: cumulative subconcussive impacts can produce delayed-onset neurodegenerative disease, and the recognition has changed how we think about the long-term consequences of head trauma in all settings — sports, military, domestic violence, and accidents.

Pitfalls and Pearls

  • CTE pathognomonic lesion: perivascular p-tau at the depths of cortical sulci, including neuronal p-tau (with or without astrocytic p-tau). Astrocytic-only sulcal-depth tau without a neuronal component = ARTAG, not CTE.
  • Phospho-tau (AT8) IHC: best for visualizing.
  • 3R + 4R tau isoforms: mixed tauopathy.
  • McKee stages I-IV: progressive cortical involvement.
  • Frontal cortex predilection: classical for CTE.
  • Cavum septum pellucidum: associated finding.
  • Traumatic encephalopathy syndrome (TES): clinical criteria for likely CTE.
  • Repetitive head impacts: cumulative (not just diagnosed concussions); subconcussive also contributes.
  • Sports: football, boxing, hockey, soccer, rugby, military blast injury, domestic violence.
  • Definite CTE: autopsy only.
  • Antemortem diagnosis: presumptive; tau PET and biomarkers emerging.
  • Differential: bvFTD, AD, mood disorders, PTSD, substance use.
  • No disease-modifying therapy; symptomatic management.
  • Prevention: reducing exposure; rule changes; helmet improvements.

References

  1. McKee AC, Cairns NJ, Dickson DW, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131(1):75-86.
  2. McKee AC, Stein TD, Crary JF, Bieniek KF, Cantu RC, Kovacs GG. Practical considerations in the neuropathologic assessment of chronic traumatic encephalopathy. Free Neuropathol. 2021;2:13.
  3. Bieniek KF, Cairns NJ, Crary JF, et al. The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol. 2021;80(3):210-219.
  4. Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA. 2017;318(4):360-370.
  5. Stern RA, Adler CH, Chen K, et al. Tau positron-emission tomography in former National Football League players. N Engl J Med. 2019;380(18):1716-1725.
  6. Katz DI, Bernick C, Dodick DW, et al. National Institute of Neurological Disorders and Stroke consensus diagnostic criteria for traumatic encephalopathy syndrome. Neurology. 2021;96(18):848-863.